tiprankstipranks
Trending News
More News >
Agilon Health Inc (AGL)
NYSE:AGL
US Market

Agilon Health (AGL) Stock Forecast & Price Target

Compare
354 Followers
See the Price Targets and Ratings of:

AGL Analyst Ratings

Hold
10Ratings
Hold
1 Buy
7 Hold
2 Sell
Based on 10 analysts giving stock ratings to
Agilon
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGL Stock 12 Month Forecast

Average Price Target

$0.98
▲(19.51% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Agilon Health in the last 3 months. The average price target is $0.98 with a high forecast of $1.50 and a low forecast of $0.50. The average price target represents a 19.51% change from the last price of $0.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.688,0.7504615384615384,0.8129230769230769,0.8753846153846153,0.9378461538461538,1.0003076923076923,1.0627692307692307,1.1252307692307693,1.1876923076923076,1.2501538461538462,1.3126153846153845,1.375076923076923,1.4375384615384617,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.688,0.7104615384615384,0.7329230769230769,0.7553846153846153,0.7778461538461539,0.8003076923076923,0.8227692307692307,0.8452307692307692,0.8676923076923077,0.8901538461538461,0.9126153846153846,0.935076923076923,0.9575384615384614,{"y":0.98,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.688,0.6735384615384615,0.659076923076923,0.6446153846153846,0.6301538461538461,0.6156923076923076,0.6012307692307692,0.5867692307692307,0.5723076923076923,0.5578461538461539,0.5433846153846154,0.5289230769230769,0.5144615384615384,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.9,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.796,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.622,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.688,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1.50Average Price Target$0.98Lowest Price Target$0.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$0.88
Hold
7.32%
Upside
Reiterated
01/06/26
Bernstein Sticks to Their Hold Rating for Agilon Health (AGL)
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
11/07/25
Agilon Health: Mixed Q3 Results and Cautious Outlook Warrant Hold Rating
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$1.5
Buy
82.93%
Upside
Reiterated
11/06/25
Agilon Health (AGL) Receives a Buy from Benchmark Co.
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
Sell
Reiterated
11/05/25
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Agilon Health (NYSE: AGL) and REPRO-MED Systems (NASDAQ: KRMD)
Evercore ISI
$1$0.5
Hold
-39.02%
Downside
Reiterated
11/05/25
Agilon Health price target lowered to 50c from $1 at Evercore ISIAgilon Health price target lowered to 50c from $1 at Evercore ISI
Barclays
$1
Sell
21.95%
Upside
Reiterated
11/05/25
Agilon Health (AGL) Receives a Sell from Barclays
Needham
Hold
Reiterated
11/05/25
Needham Reaffirms Their Hold Rating on Agilon Health (AGL)
TD Cowen
$1
Hold
21.95%
Upside
Reiterated
11/05/25
Agilon Health: Hold Rating Amid Mixed Financial Outlook and Strategic Adjustments
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
Hold
Reiterated
11/05/25
Truist Financial Reaffirms Their Hold Rating on Agilon Health (AGL)
BTIG
Hold
Assigned
11/04/25
Agilon Health: Hold Rating Amid Cost Pressures and Uncertain Turnaround Efforts
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$5$1.5
Buy
82.93%
Upside
Reiterated
10/06/25
Agilon Health price target lowered to $1.50 from $5 at Wells FargoAgilon Health price target lowered to $1.50 from $5 at Wells Fargo
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
Hold
Reiterated
08/22/25
Balanced Outlook for Agilon Health Amid Market Stability and Challenges
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$2.4$1.1
Hold
34.15%
Upside
Reiterated
08/15/25
Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
Robert W. Baird Analyst forecast on AGL
Robert W. Baird
Robert W. Baird
$5$1
Hold
21.95%
Upside
Reiterated
08/14/25
Agilon Health price target lowered to $1 from $5 at BairdAgilon Health price target lowered to $1 from $5 at Baird
Goldman Sachs Analyst forecast on AGL
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$5$1
Hold
21.95%
Upside
Reiterated
08/12/25
Goldman Sachs Keeps Their Hold Rating on Agilon Health (AGL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$0.88
Hold
7.32%
Upside
Reiterated
01/06/26
Bernstein Sticks to Their Hold Rating for Agilon Health (AGL)
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
11/07/25
Agilon Health: Mixed Q3 Results and Cautious Outlook Warrant Hold Rating
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$1.5
Buy
82.93%
Upside
Reiterated
11/06/25
Agilon Health (AGL) Receives a Buy from Benchmark Co.
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
Sell
Reiterated
11/05/25
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Agilon Health (NYSE: AGL) and REPRO-MED Systems (NASDAQ: KRMD)
Evercore ISI
$1$0.5
Hold
-39.02%
Downside
Reiterated
11/05/25
Agilon Health price target lowered to 50c from $1 at Evercore ISIAgilon Health price target lowered to 50c from $1 at Evercore ISI
Barclays
$1
Sell
21.95%
Upside
Reiterated
11/05/25
Agilon Health (AGL) Receives a Sell from Barclays
Needham
Hold
Reiterated
11/05/25
Needham Reaffirms Their Hold Rating on Agilon Health (AGL)
TD Cowen
$1
Hold
21.95%
Upside
Reiterated
11/05/25
Agilon Health: Hold Rating Amid Mixed Financial Outlook and Strategic Adjustments
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
Hold
Reiterated
11/05/25
Truist Financial Reaffirms Their Hold Rating on Agilon Health (AGL)
BTIG
Hold
Assigned
11/04/25
Agilon Health: Hold Rating Amid Cost Pressures and Uncertain Turnaround Efforts
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$5$1.5
Buy
82.93%
Upside
Reiterated
10/06/25
Agilon Health price target lowered to $1.50 from $5 at Wells FargoAgilon Health price target lowered to $1.50 from $5 at Wells Fargo
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
Hold
Reiterated
08/22/25
Balanced Outlook for Agilon Health Amid Market Stability and Challenges
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$2.4$1.1
Hold
34.15%
Upside
Reiterated
08/15/25
Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
Robert W. Baird Analyst forecast on AGL
Robert W. Baird
Robert W. Baird
$5$1
Hold
21.95%
Upside
Reiterated
08/14/25
Agilon Health price target lowered to $1 from $5 at BairdAgilon Health price target lowered to $1 from $5 at Baird
Goldman Sachs Analyst forecast on AGL
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$5$1
Hold
21.95%
Upside
Reiterated
08/12/25
Goldman Sachs Keeps Their Hold Rating on Agilon Health (AGL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilon Health

1 Month
xxx
Success Rate
9/22 ratings generated profit
41%
Average Return
-3.24%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.91% of your transactions generating a profit, with an average return of -3.24% per trade.
3 Months
xxx
Success Rate
5/14 ratings generated profit
36%
Average Return
-2.77%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -2.77% per trade.
1 Year
Stephen BaxterWells Fargo
Success Rate
0/22 ratings generated profit
0%
Average Return
-60.75%
reiterated a buy rating 3 months ago
Copying Stephen Baxter's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -60.75% per trade.
2 Years
xxx
Success Rate
0/22 ratings generated profit
0%
Average Return
-75.94%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -75.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGL Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
4
1
1
1
1
Buy
2
3
2
1
0
Hold
21
23
17
16
13
Sell
3
3
3
3
3
Strong Sell
0
0
0
0
0
total
30
30
23
21
17
In the current month, AGL has received 1 Buy Ratings, 13 Hold Ratings, and 3 Sell Ratings. AGL average Analyst price target in the past 3 months is 0.98.
Each month's total comprises the sum of three months' worth of ratings.

AGL Financial Forecast

AGL Earnings Forecast

Next quarter’s earnings estimate for AGL is -$0.27 with a range of -$0.31 to -$0.23. The previous quarter’s EPS was -$0.27. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s earnings estimate for AGL is -$0.27 with a range of -$0.31 to -$0.23. The previous quarter’s EPS was -$0.27. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Sales Forecast

Next quarter’s sales forecast for AGL is $1.46B with a range of $1.42B to $1.54B. The previous quarter’s sales results were $1.44B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s sales forecast for AGL is $1.46B with a range of $1.42B to $1.54B. The previous quarter’s sales results were $1.44B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Stock Forecast FAQ

What is AGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilon Health Inc’s 12-month average price target is 0.98.
    What is AGL’s upside potential, based on the analysts’ average price target?
    Agilon Health Inc has 19.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGL a Buy, Sell or Hold?
          Agilon Health Inc has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 2 sell ratings.
            What is Agilon Health Inc’s price target?
            The average price target for Agilon Health Inc is 0.98. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1.50 ,the lowest forecast is $0.50. The average price target represents 19.51% Increase from the current price of $0.82.
              What do analysts say about Agilon Health Inc?
              Agilon Health Inc’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of AGL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.